Genmab — November 2018
-
Børsen analyse 9.39. https://borsen.dk/
-
Jan har sagt at det, mellem JNJ og Genmab, er fastlagt hvad der skal ske, såfremt de helt uventet taber. JNJ tager så godt som hele regningen, og Genmab vil kun få en minimal påvirkning. Skulle det ske, har det lydt, at det vil være i størrelsesordenen 2-3 pct. ialt. Altså bør minimal for Genmab være en del lavere end 1.
-
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind